Sotera Health (SHC)
(Real Time Quote from BATS)
$11.42 USD
+0.48 (4.39%)
Updated Apr 23, 2024 11:02 AM ET
4-Sell of 5 4
D Value D Growth D Momentum F VGM
Income Statements
Fiscal Year end for Sotera Health Company falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,049 | 1,004 | 931 | 818 | 778 |
Cost Of Goods | 472 | 447 | 413 | 375 | 383 |
Gross Profit | 577 | 557 | 519 | 444 | 395 |
Selling & Adminstrative & Depr. & Amort Expenses | 300 | 309 | 262 | 238 | 212 |
Income After Depreciation & Amortization | 277 | 248 | 257 | 206 | 184 |
Non-Operating Income | -28 | -411 | -7 | -30 | -27 |
Interest Expense | 143 | 80 | 74 | 215 | 158 |
Pretax Income | 106 | -243 | 176 | -39 | -1 |
Income Taxes | 55 | -10 | 59 | -1 | 20 |
Minority Interest | 0 | 0 | 0 | 1 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 51 | -234 | 117 | -37 | -20 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 51 | -234 | 117 | -39 | -21 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 444 | 409 | 414 | 361 | 339 |
Depreciation & Amortization (Cash Flow) | 167 | 161 | 157 | 155 | 155 |
Income After Depreciation & Amortization | 277 | 248 | 257 | 206 | 184 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 283.22 | 280.10 | 279.38 | 237.70 | NA |
Diluted EPS Before Non-Recurring Items | 0.72 | 0.90 | 0.84 | 0.38 | NA |
Diluted Net EPS (GAAP) | 0.18 | -0.83 | 0.41 | -0.16 | -0.09 |
Fiscal Year end for Sotera Health Company falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 310.24 | 263.18 | 255.28 | 220.59 |
Cost Of Goods | NA | 130.16 | 117.19 | 115.69 | 109.09 |
Gross Profit | NA | 180.08 | 145.98 | 139.59 | 111.50 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 76.06 | 69.88 | 76.39 | 78.14 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 104.02 | 76.10 | 63.20 | 33.36 |
Non-Operating Income | NA | 4.30 | -35.00 | 2.01 | 0.91 |
Interest Expense | NA | 42.65 | 40.63 | 30.73 | 28.87 |
Pretax Income | NA | 65.67 | 0.47 | 34.49 | 5.40 |
Income Taxes | NA | 26.99 | 14.13 | 10.97 | 2.56 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 38.68 | -13.66 | 23.51 | 2.84 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 38.68 | -13.66 | 23.51 | 2.84 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 283.34 | 281.11 | 283.15 | 282.98 |
Diluted EPS Before Non-Recurring Items | NA | 0.24 | 0.18 | 0.19 | 0.11 |
Diluted Net EPS (GAAP) | NA | 0.14 | -0.05 | 0.08 | 0.01 |